Close
Almac
Achema middle east

New Antibiotic Discovery Helped By Australia Sepsis Study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

Researchers from the University of Queensland in Australia have led a national study pertaining to four major bacteria that cause sepsis, thereby providing new targets when it comes to developing antibiotics.

Professor Mark Schembri and Professor Mark Walker from the university’s Institute of Molecular Biosciences, along with the University of Melbourne’s Dr. Andre Mu and teams from 23 organisations across Australia, had set up experiments in order to mimic what takes place to bacteria as and when they enter the blood stream during the course of the infection.

It is well to be noted that sepsis is the root cause of 20% of the deaths across the world, in which people succumb to heart attacks, strokes, colon, breast, or prostate cancer. It is often characterised by infection-led organ failure, leaving survivors with cognitive, physical, and psychological side effects that can be seen for the rest of their lives.

Apparently, the researchers have been able to characterise RNA, bacterial genes, proteins, and metabolites from E. coli, Klebsiella pneumoniae, Group A Streptococcus, as well as Staphylococcus, and combined the data so as to get an absolute picture of how different species go on to respond when grown in human blood serum.

The research also brought together the biological sciences communities and Australian bacterial-pathogen research and generated loads of data, which happens to be publicly accessible. Due to this, researchers from across the world will be able to pry out this dataset so as to drive antibiotic exploration and development, which is very pivotal considering the fast rise in antibiotics seen worldwide.

Notably, the antibiotic-resistant sepsis pathogens framework initiative consortium is very well supported due to the funding received from the Australian Government’s National Collaboration research infrastructure strategy led Bioplatforms Australia.

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »